La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

CH Biotech R&D Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Cho-Chun Huang

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	3yrs
Proprietà del CEO	0.04%
Durata media del management	5.8yrs
Durata media del Consiglio di amministrazione	3yrs

Aggiornamenti recenti sulla gestione

Recent updates

CH Biotech R&D (GTSM:6534) Takes On Some Risk With Its Use Of Debt

Apr 05

A Look At CH Biotech R&D's (GTSM:6534) Share Price Returns

Mar 18

Are CH Biotech R&D Co., Ltd.'s (GTSM:6534) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Feb 09

Returns On Capital At CH Biotech R&D (GTSM:6534) Paint An Interesting Picture

Jan 11

Does CH Biotech R&D (GTSM:6534) Have A Healthy Balance Sheet?

Dec 15

Tread With Caution Around CH Biotech R&D Co., Ltd.'s (GTSM:6534) 1.8% Dividend Yield

Nov 24

AMMINISTRATORE DELEGATO

Cho-Chun Huang

3yrs

Mandato

Ms. Cho-Chun Huang serves as the President at CH Biotech R&D Co., Ltd. since September 1, 2021. She was Chief of R&D Department at CH Biotech R&D Co., Ltd.since December 17, 2019 until June 1, 2021. Ms. H...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Cho-Chun Huang	President	3yrs	Nessun dato	0.036% NT$ 2.8m
Hsiu-Feng Lin	Assistant Vice President of Finance Department	7yrs	Nessun dato	Nessun dato
Xinjun Luo	Accounting Supervisor	no data	Nessun dato	Nessun dato
Mu-Sheng Lin	Chief of Board Office	6.9yrs	Nessun dato	Nessun dato
Kuei-Chun Li	Head of R&D Department	4.8yrs	Nessun dato	Nessun dato

5.8yrs

Durata media

Gestione esperta: Il team dirigenziale di 6534 è esperto e expertise (durata media dell'incarico 5.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Cheng-Pang Wu	Chairman	10.8yrs	Nessun dato	20.62% NT$ 1.6b
Chao-Tsung Chiu	Director	6.3yrs	Nessun dato	0.15% NT$ 11.8m
Yung Ming Chou	Director	4yrs	Nessun dato	Nessun dato
Yong-Xiang Chiu	Independent Director	3yrs	Nessun dato	Nessun dato
Robert James Christopher Clayton	Institutional Director	1.3yrs	Nessun dato	Nessun dato
Wanyu Liu	Independent Director	no data	Nessun dato	Nessun dato
Yin-Hsiang Chou	Independent Director	no data	Nessun dato	Nessun dato
Jesse Wu	Director	less than a year	Nessun dato	Nessun dato
Wei-Tun Yeh	Director	less than a year	Nessun dato	Nessun dato

3.0yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 6534 sono considerati esperti (durata media dell'incarico 3 anni).

CH Biotech R&D Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

CH Biotech R&D Co., Ltd., Annual General Meeting, May 21, 2024

Less than half of directors are independent

Less than half of directors are independent

CH Biotech R&D Co., Ltd., Annual General Meeting, Jun 08, 2022

CH Biotech R&D Co., Ltd., Annual General Meeting, May 28, 2021

Recent updates

Upcoming dividend of NT$0.50 per share

Second quarter 2024 earnings released: EPS: NT$1.27 (vs NT$1.96 in 2Q 2023)

CH Biotech R&D Co., Ltd. to Report Q2, 2024 Results on Aug 06, 2024

Now 20% overvalued

First quarter 2024 earnings released: EPS: NT$4.08 (vs NT$4.05 in 1Q 2023)

CH Biotech R&D Co., Ltd. to Report Q1, 2024 Results on May 07, 2024

Upcoming dividend of NT$3.09 per share

Full year 2023 earnings released: EPS: NT$4.76 (vs NT$4.79 in FY 2022)

Dividend of NT$3.09 announced

CH Biotech R&D Co., Ltd. Approves Cash Dividend for the Second Half of 2023, Payable on April 12, 2024

CH Biotech R&D Co., Ltd., Annual General Meeting, May 21, 2024

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 18%

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Third quarter 2023 earnings released: NT$0.45 loss per share (vs NT$0.30 loss in 3Q 2022)

New minor risk - Shareholder dilution

Upcoming dividend of NT$1.00 per share at 2.6% yield

Second quarter 2023 earnings released: EPS: NT$1.96 (vs NT$3.44 in 2Q 2022)

CH Biotech R&D Co., Ltd. Approves Cash Dividend for the First Half Ended June 30, 2023

Full year 2022 earnings released: EPS: NT$4.79 (vs NT$3.00 in FY 2021)

Upcoming dividend of NT$3.88 per share at 4.7% yield

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: NT$6.22 (vs NT$2.56 in 1H 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Upcoming dividend of NT$1.50 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

CH Biotech R&D Co., Ltd., Annual General Meeting, Jun 08, 2022

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS NT$2.94 (vs NT$2.12 in 1H 2020)

Investor sentiment improved over the past week

Upcoming dividend of NT$0.50 per share

Investor sentiment improved over the past week

CH Biotech R&D (GTSM:6534) Takes On Some Risk With Its Use Of Debt

Full year 2020 earnings released: EPS NT$1.19 (vs NT$2.26 in FY 2019)

A Look At CH Biotech R&D's (GTSM:6534) Share Price Returns

CH Biotech R&D Co., Ltd., Annual General Meeting, May 28, 2021

New 90-day low: NT$50.00

Are CH Biotech R&D Co., Ltd.'s (GTSM:6534) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Returns On Capital At CH Biotech R&D (GTSM:6534) Paint An Interesting Picture

New 90-day low: NT$52.10

Does CH Biotech R&D (GTSM:6534) Have A Healthy Balance Sheet?

Tread With Caution Around CH Biotech R&D Co., Ltd.'s (GTSM:6534) 1.8% Dividend Yield

New 90-day high - NT$69.30

First half earnings released

Upcoming Dividend of NT$1.10 Per Share

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media